Centessa Q1 net loss $26.1M; cash $424.9M; OX2R agonist pipeline on track for 2025 data

Centessa Pharmaceuticals plc

2025-Q1 EPS reported -$0.20 revenue$15,000,000

Net loss narrowed to $26.1M from $38.0M in Q1 2024, with no product revenue.
Cash, equivalents and investments totaled $424.9M, expected to fund operations into mid-2027.
R&D expenses increased to $33.4M from $22.7M, driven by pipeline advancement.
ORX750 Phase 2a CRYSTAL-1 study ongoing; data from narcolepsy NT1, NT2 and IH anticipated in 2025.
ORX142 first-in-human studies planned in 2025 with data from sleep-deprived healthy volunteers expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.